Semaglutide is a GLP-1 receptor agonist that helps people lose an average of 15% of their body weight, but gastrointestinal side effects affect up to 40% of users during the first 4 weeks of treatment
The FDA didnt approve daily use of GLP-1 receptor agonist for good reasons
Try Greek yogurt, soft oats, scrambled eggs, chicken soup, rice bowls, cottage cheese, protein shakes, or broth-based meals
Byetta (active ingredient: exenatide synthetic) subcutaneous injection
Furthermore, it is well-established that many of these species can give rise to secondary oxidants with different reactivity and lifespan than the initial ones (reviewed in Halliwell and Gutteridge, 2015)